the publication�s purpose is to be a "force for good and a platform for much needed change and to generate critical debate".
.: "arise: a phase 3 randomized trial of erenumab for episodic migraine."
.
why novartis� landmark cancer drug approval is great news for bluebird
.
.
.
.
.